Wells Fargo lowered the firm’s price target on Keros Therapeutics (KROS) to $20 from $23 and keeps an Overweight rating on the shares. The firm notes no change to its thesis. Wells expects bearish sentiment to remain over the near term. Longer term, it looks to DMD data from rinvatercept to reset the narrative. The planned Phase 2 is open label and the firm thinks setting up readouts in 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
- KROS Upcoming Earnings Report: What to Expect?
- Keros Therapeutics Adds Veteran Finance Leader to Board
- Keros Therapeutics CEO to Present at Multiple Conferences
- Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation